We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
all of my substantial holding is in my SIPP so thankyou everyone for contributing 40% of it ;o-)
I hope so, the MM know ThinkEquity might call them any minute and drop some shares on the market. So hopefully they will have to stay short.. Its just like the Stock markes rally after Trump got in or post CvD-19. Everyone expecting it to dump and all of a sudden we are 30% up and people didnt get on the train ...
That would give the Company a market capitalisation of 3.9 billion pounds. It is possible, if you wish to hold for 10+ years.
Tofay could be a huge jump. Everything is coming together and the market is still behind the curve.
120p is a tough nut to crack ...
Even Manabouttown can't manage it ...
Patience Patience is my motto
"They are very unlikely to back date any cut off for free shares."
It is against UK Company Law t have a restrospective record date so I agree, very unlikely, unless they wish to break the law, which I doubt they will do.
Question, i have £15k that I'am about to purchase more Tiz shares with, However I'am slightly confused as to weather they can back date the Stemprint (free shares), and if so is this already factored into the price? Or would we expect a slight drop after news?
Cheers
Will be 107% soon...
I took another 6k shares first thing at 1.1495...not shown
Like having a early morning rns :-)
Should be one of those life changing days
City was reading it never checked you had already posted it :-)
Explains the rise and only way is up now gla
See today's BioWorld
Regeneron halts one phase III COVID-19 trial while starting two others
July 6, 2020
By Lee Landenberger
Missing the primary endpoint along with key secondary endpoints in a phase III trial of Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antibody, for treating COVID-19 patients who need mechanical ventilation caused Regeneron Pharmaceuticals Inc. and Sanofi SA to halt the study.
Tarrytown, N.Y.-based Regeneron then followed the closing by initiating two late-stage studies, a phase III and a phase II/III, to evaluate REGN-CoV2, a double antibody ****tail for treating and preventing COVID-19.
The stumble produced a good day for Tiziana Life Sciences plc (NASDAQ:TLSA), whose stock rose 9.6% July 6, closing at $7.19 a share. London-based Tiziana is developing its own anti-IL-6 receptor monoclonal antibody, TZLS-501, to be delivered directly into the lungs of a COVID-19 patient using an inhaler or nebulizer. In April, the company filed a patent application to support the treatment.